SuperworthInogen profit margin INGN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- −6.9%
- Operating margin, 12 months
- −8.7%
- Net margin on a year earlier
- +0.6 pts
- Peer median
- 6.9%
Over the twelve months to Jun 30, 2026, Inogen kept −6.9% of its revenue as net profit, with an operating margin of −8.7% and a gross margin of 44.5%.
Five years earlier its net margin was −0.7%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −6.5% | −8.7% | 44.2% |
| FY2024 | −10.7% | −12.7% | 46.1% |
| FY2023 | −32.5% | −34.7% | 40.1% |
| FY2022 | −22.2% | −22.6% | 40.7% |
| FY2021 | −1.8% | 2.6% | 49.3% |
| FY2020 | −1.9% | −3.9% | 44.8% |
| FY2019 | 5.8% | 5.5% | 47.5% |
| FY2018 | 14.5% | 10.6% | 49.9% |
| FY2017 | 8.4% | 11.1% | 48.6% |
| FY2016 | 10.1% | 11.3% | 48.0% |
| FY2015 | 7.3% | 9.5% | 48.0% |
| FY2014 | 6.1% | 9.3% | 49.3% |
| FY2013 | 33.7% | 5.9% | 51.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −6.9% | +0.6 pts | −8.7% | |
| Q1 FY26 | −7.1% | +1.0 pts | −9.1% | |
| Q4 FY25 | −6.5% | +4.2 pts | −8.7% | |
| Q3 FY25 | −7.3% | +8.6 pts | −9.3% | |
| Q2 FY25 | −7.6% | +20.7 pts | −9.6% | |
| Q1 FY25 | −8.1% | +22.0 pts | −10.0% | |
| Q4 FY24 | −10.7% | +21.8 pts | −12.7% | |
| Q3 FY24 | −15.9% | +24.5 pts | −18.1% | |
| Q2 FY24 | −28.3% | −0.7 pts | −30.3% | |
| Q1 FY24 | −30.1% | −5.7 pts | −32.3% | |
| Q4 FY23 | −32.5% | −10.2 pts | −34.7% | |
| Q3 FY23 | −40.4% | −26.7 pts | −42.4% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Inogen's size, closest first, today.
| Company | Profit margin |
|---|---|
| INGNInogen | −6.9% |
| PDEXPro DEX | 17.6% |
| UTMDUtah Medical Products | 29.0% |
| INFUInfuSystem | 6.0% |
| KEQUKewaunee Scientific | 3.0% |
| EMBCEmbecta | 8.6% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| APTAlpha Pro Tech | 6.8% |
| MOVMovado | 6.0% |
| NEPHNephros | 8.4% |
| Peer median | 6.9% |
Where Inogen ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Inogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.